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Tumor Necrosis factor receptor: Fc fusion protein does not
improve septic shock and may increase mortality in human
The importance of knowing and understanding thephysiopathology of diseases is obvious. Whenrelevant, new information is integrated and
hypotheses are generated, particularly with the aim of
interfering in the disease process. Thus, hope of preventing
or treating the disease arises. But before evidence
concerning efficacy is obtained, there is a strong tendency
to apply the results in practice.
This scenario is illustrated by a recently published
article on the treatment of septic shock with the tumor
necrosis factor receptor (TNFR:Fc).1 As it is known, the
administration of TNF2 may reproduce various aspects of
shock pathogenes.2.3 As the article states, TNF antibodies
have a protective effect in animal models of septic shock.4.5
Thus, interfering with TNF effects became a great
hope in the treatment of septic shock. Yet when the safety
and efficacy ofTNFR:Fc was tested in humans, using three
different doses in a randomized controlled trial (RCT)
against placebo, no effect on mortality was observed at
the lower doses, and indeed the high dose appeared to be
associated with increased mortality.
Although the study group sample size was relatively
small, there is only a small probability that this kind of
treatment may help, rather than harm septic shock patients.
Thus, this hope, obtained after many years of high
technology research, has been shattered.
While the importance of blocking the TNF effect,
after the mastocite has been stimulated, may be
reevaluated, further research and new hope are needed and
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again, as in this case, the use of RCTs will distinguish
between theoretical and true efficacy.
While it may be difficult and laborious to accept, the
best way to know whether a new treatment is good or not
is to test the hypothesis by designing and conducting a
RCT. Theoretical hypotheses are important pathways for
research question formulations which eventually must be
tested by RCTs.
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